Interleukin 28B Genetic Polymorphisms Play a Minor Role in Identifying Optimal Treatment Duration in HCV Genotype 1 Slow Responders to Pegylated Interferon plus Ribavirin | Zendy

ChenHua Liu | Zendy; ChengChao Liang | Zendy; ChunJen Liu | Zendy; TaiChung Tseng | Zendy; ChihLin Lin | Zendy; ShengShun Yang | Zendy; TungHung Su | Zendy; JouWei Lin | Zendy; Jun-Herng Chen | Zendy; PeiJer Chen | Zendy; DingShinn Chen | Zendy; JiaHorng Kao | Zendy

Open Access

Interleukin 28B Genetic Polymorphisms Play a Minor Role in Identifying Optimal Treatment Duration in HCV Genotype 1 Slow Responders to Pegylated Interferon plus Ribavirin

Author(s) -

ChenHua Liu,

ChengChao Liang,

ChunJen Liu,

TaiChung Tseng,

ChihLin Lin,

ShengShun Yang,

TungHung Su,

JouWei Lin,

Jun-Herng Chen,

PeiJer Chen,

DingShinn Chen,

JiaHorng Kao

Publication year - 2012

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2322

Subject(s) - ribavirin , pegylated interferon , medicine , interleukin 28b , viral load , gastroenterology , genotype , snp , hepatitis c virus , immunology , single nucleotide polymorphism , biology , virus , biochemistry , gene

Pegylated interferon and ribavirin for 72 weeks improve sustained virological response (SVR) in HCV genotype 1 (HCV-1) slow viral responders. Whether interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and on-treatment viral responses can identify non-rapid virological response (RVR) patients who benefit from 48 or 72 weeks of therapy remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research